Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s share price was up 4.5% during trading on Wednesday . The stock traded as high as $67.49 and last traded at $68.73. Approximately 1,838,348 shares were traded during trading, an increase of 42% from the average daily volume of 1,294,130 shares. The stock had previously closed at $65.76.

Several equities analysts recently commented on ICPT shares. Cowen and Company reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC reissued a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research report on Sunday, July 30th. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target on the stock in a research report on Tuesday, July 11th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $162.88.

The stock’s 50 day moving average is $93.18 and its 200-day moving average is $110.81. The stock’s market cap is $1.83 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the company earned ($3.14) EPS. The company’s quarterly revenue was up 459.6% on a year-over-year basis. On average, equities research analysts predict that Intercept Pharmaceuticals, Inc. will post ($13.98) earnings per share for the current year.

In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders sold a total of 6,920 shares of company stock valued at $672,822 in the last quarter. Corporate insiders own 9.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. WFG Advisors LP lifted its position in shares of Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Intercept Pharmaceuticals by 14.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. US Bancorp DE bought a new position in shares of Intercept Pharmaceuticals during the 1st quarter worth approximately $130,000. IFP Advisors Inc lifted its position in shares of Intercept Pharmaceuticals by 128.1% during the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Intercept Pharmaceuticals during the 1st quarter worth approximately $170,000. Institutional investors and hedge funds own 82.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Trading Up 4.5%” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/intercept-pharmaceuticals-inc-icpt-trading-up-4-5/1611663.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.